Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Trump Considering Dr. Scott Gottlieb to Head U.S. FDA

Toni Clarke  |  December 12, 2016

(Reuters)—Dr. Scott Gottlieb, a partner at one of the world’s largest venture capital funds and a former deputy commissioner at the U.S. Food and Drug Administration, is being considered by President-Elect Donald Trump to run the agency, according to sources close to the transition team. Gottlieb, 44, a venture partner at New Enterprise Associates and…

Japan PM’s Advisers Urge Annual Review of Drug Prices

Reuters Staff  |  December 8, 2016

TOKYO (Reuters)—Prime Minister Shinzo Abe’s economic advisers, hoping to curb Japan’s ballooning healthcare costs, proposed on Wednesday reforms to the way drug prices are set, a step opposed by foreign and domestic drug makers who say the changes will stifle investment. The proposals follow a decision to halve the price of Bristol Myers Squibb Co’s…

Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab

Marilynn Larkin  |  December 8, 2016

NEW YORK (Reuters Health)—Compared with cyclophosphamide, rituximab treatment poses less malignancy risk in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), European researchers report. Dr. Emma E. van Daalen of Leiden University Medical Center in the Netherlands tells Reuters Health, “Previous studies reported an increased malignancy risk in patients with AAV, which has been associated…

U.S. Insurer Lobby Group Seeks Delay in 2018 Obamacare Deadline

Caroline Humer  |  December 7, 2016

NEW YORK (Reuters)—The largest lobbying group for health insurers has asked U.S. lawmakers weighing the fate of Obamacare to push back the due date for 2018 individual insurance submissions to regulators in hopes of obtaining greater clarity on the program’s future later on. Republican leaders including President-elect Donald Trump and U.S. Senate Majority Leader Mitch…

RISE Registry Promises to Improve Care & Research for Rheumatology

Arthritis Care & Research  |  December 6, 2016

In 2014, the ACR launched the Rheumatology Informatics System for Effectiveness (RISE), a national electronic health record (EHR)-enabled registry. The goal: To help participating rheumatologists and practices leverage the new wave of big data created by the use of EHR, advance research and improve overall quality of care. A new analysis examines the RISE structure and the initial patient data collected by the registry…

U.S. Court Puts Obamacare Case On Hold Until Trump Takes Office

Lawrence Hurley  |  December 5, 2016

WASHINGTON (Reuters)—A federal appeals court on Monday brought to an end President Barack Obama’s bid to overturn a ruling that threatens to gut his signature healthcare law by putting the case on hold until after President-Elect Donald Trump, who aims to repeal Obamacare, takes office. The Obama administration had appealed a judge’s May ruling favoring…

Heparin Fails to Prevent Leg, Lung Clots After Arthroscopy, Casting

Gene Emery  |  December 5, 2016

NEW YORK (Reuters Health)—Low-molecular-weight heparin failed to prevent symptomatic venous thromboemboli in people receiving knee arthroscopy or a lower leg cast, according to a pair of studies conducted in the Netherlands. The treatment is controversial because there is little clear evidence that heparin wards off clots in such instances. The research team, led by Dr. Raymond…

Verdict: Johnson & Johnson to Pay More Than $1 Billion for Defective Hip Implants

Erica Teichert  |  December 4, 2016

(Reuters)—A federal jury in Dallas on Thursday ordered Johnson & Johnson (J&J) and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants. The jurors found that the metal-on-metal Pinnacle hip implants were defectively designed and that the companies failed to warn consumers…

Senator Warns Against Simultaneous Overhaul of Medicare & Obamacare

Susan Cornwell  |  December 3, 2016

WASHINGTON (Reuters)—A senior U.S. Senator warned his on Thursday against simultaneously overhauling Medicare and the Obamacare health insurance program, saying this would be “biting off more than you can chew.” The cautionary comments from Sen. Lamar Alexander (R-Tenn.) came after House Speaker Paul Ryan, long an advocate of privatizing Medicare, said Republican lawmakers would be…

Teva Pharm to Market Medical Cannabis Inhaler in Israel

Reuters Staff  |  November 28, 2016

JERUSALEM (Reuters)—Israel’s Teva Pharmaceuticals has partnered with Tel Aviv-based Syqe Medical to market in Israel medical cannabis for pain management that is administered with an inhaler. The companies said in a statement on Monday that this is the first time the medical cannabis sector has complied with pharmaceutical standards for inhalation, which is the most…

  • « Previous Page
  • 1
  • …
  • 53
  • 54
  • 55
  • 56
  • 57
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences